Organogenesis Holdings Inc.
- ORGO
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Regenerative Medicine
- Wound Care
- Tissue Repair
$1.02
Today +2.03%Quote Oct 19, 2026, 08:00 PM UTC
−26.49%over the last month
Max drawdown −32.5%From 1-month high −32.5%3 months −62.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Organogenesis
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products.
Where the money comes from
Q2 2026 revenue $43.8M
- Product$42.8M97.8%
- Grant$950,0002.2%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
854
Market value
$131.2M
Quote Oct 19
Resistance
$1.09
6.9% above price
Price vs analyst targets
6 analysts
Lowest target
$2.00Highest target
$3.00
$2.00Highest target
$3.00
- Price $1.02
- Average target $2.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 145% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ORGOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free